

Announcements.

Looking to discover a little more about our client companies?
A selection of news and recent announcements can be found here.
Sprue Aegis plc : Product Testing Completed
RNS Number : 1197X Sprue Aegis plc 04 May 2016 4 May 2016 Sprue Aegis plc ("Sprue", the "Company" or the "Group") Product Testing Completed Sprue (AIM: SPRP), one of Europe's leading home safety products suppliers, announces that it has been notified that the Company has completed the……
RNS Number : 1197X
Sprue Aegis plc
04 May 2016
4 May 2016
Sprue Aegis plc
("Sprue", the "Company" or the "Group")
Product Testing Completed
Sprue (AIM: SPRP), one of Europe's leading home safety products suppliers, announces that it has been notified that the Company has completed the final key testing milestone of its new European product variants. In accordance with the standard process, receipt of formal paperwork and certification documentation will follow which will allow full scale manufacturing production to commence.
– Ends –
For further information, please contact:
Sprue Aegis plc 0247 771 7700
Graham Whitworth, Executive Chairman
Neil Smith, Group Chief Executive
John Gahan, Group Finance Director
Stockdale Securities 020 7601 6100
Tom Griffiths
Notes to Editors
About Sprue Aegis plc
Sprue's mission is to protect, save and improve our customers' lives by making innovative, leading edge technology simple and accessible.
Sprue is one of the market leaders in the European home safety products market. Its principal products are smoke alarms and CO alarms and accessories and the Group has an extensive portfolio of patented intellectual property. Sprue has patented its technology in Europe, the US and other selected territories.
The introduction of new technologically advanced products and new safety products legislation in the UK and in Europe, and increasing levels of awareness of the dangers of smoke and CO, continue to drive sales.
Sprue manufactures CO sensors at its subsidiary, Pace Sensors for use in its CO alarms. All other manufacturing and product assembly is outsourced to two principal third party contract manufacturers in China, one of which is Jarden Corporation which owns 23.6% of the Group and Pace Technology which is independent from Jarden Corporation.
Sprue enjoys a leading sales footprint in UK Retail and the UK's Fire & Rescue Services. The Group also supplies the UK's Utility and Leisure sector which includes customers such as British Gas and Scottish Gas and has a well-established but relatively low market share of the UK Trade sector. Sprue has a rapidly growing business in Continental Europe mainly selling through a network of independently owned third party distributors
The Group has won a number of prestigious Sunday Times Virgin Fast Track 100 Awards, which recognises the 100 fastest growing companies in the UK. Sprue's head office is in Coventry and it has a second office in Gloucester. Warehousing is located in Cambridge and Gloucester
Sprue's range of products is comprehensive, allowing the Group to tailor the range of smoke alarms, CO alarms and accessories to suit its customer needs at various price points under the following brands:
Ø FireAngel. A market-leading and innovative battery operated alarm principally targeted at UK Retail and UK F&RS
Ø AngelEye. Launched in 2012, Sprue sells smoke alarms and CO detectors principally into the French market under the AngelEye brand and to Sainsburys in the UK. AngelEye has become a leading brand targeted at the DIY channel in France
Ø SONA. A new, low power mains powered range of smoke and heat alarm products plus CO detection that are market leading and which can be wirelessly interconnected with up to 50 products on a single network
Ø FireAngel Pro. Mains-powered smoke alarm with a 10 year, sealed for life lithium battery back-up. Modern design, quick fitting, tamper-proof mounting plate which locks the alarm head securely in place. Mounting plate has wide, easily accessible connection to the mains feed. Cable knock-out allows for compatibility with YT2 cable trunking
Ø Pace Sensors. CO sensors used within Sprue's CO products are developed by Sprue and Pace Sensors, Sprue's wholly owned subsidiary in Canada. Pace Sensors' CO sensors are used within all FireAngel, AngelEye and Pace Sensors CO detectors and certain First Alert branded CO detectors
Sprue has the exclusive rights to distribute the products and brands of BRK Brands Europe Limited (a subsidiary of Jarden Corporation) in Europe namely, First Alert, BRK and Dicon. First Alert is one of the leading safety products brands in North America.
For further product information, please visit: www.sprue.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCAJMATMBJMBIF
CloseTrakm8 Holdings PLC : Contract Win
RNS Number : 8920W Trakm8 Holdings PLC 03 May 2016 TRAKM8 HOLDINGS PLC ("Trakm8" or the "Group") ScottishPower Awards Trakm8 Telematics Contract Trakm8, the AIM quoted telematics and data provider to the global market place, is pleased to announce it has been awarded an initial four……
RNS Number : 8920W
Trakm8 Holdings PLC
03 May 2016
TRAKM8 HOLDINGS PLC
("Trakm8" or the "Group")
ScottishPower Awards Trakm8 Telematics Contract
Trakm8, the AIM quoted telematics and data provider to the global market place, is pleased to announce it has been awarded an initial four year contract by ScottishPower to supply Fleet tracking and driver behavior solutions for 1,608 vehicles.
ScottishPower is part of the Iberdrola Group and is one of the UK's leading utility companies, working often in extreme weather conditions. Telematics are expected to play a significant part in improving operational efficiency and management of the technical fleet.
Trakm8 will provide hardware and data services based on the very latest T10 and Light bar hardware and Trakm8's innovative risk and vehicle service data analysis tools. The vehicle hardware installation will take place during H1 of 2016.
John Watkins, Executive Chairman of Trakm8 commented:
"We are delighted to have ScottishPower as a customer for Trakm8's commercial vehicle fleet telematics solutions. We have been providing telematics to major fleets for many years but this is the first major customer for our full function T10 product and Swift 6 driver profiling. This contract provides additional visibility for our expectations for the current financial year."
John Moore, Vehicle Maintenance Manager of ScottishPower commented:
"We undertook a rigorous supplier selection process and are pleased to have selected, what we believe, to be the best value telematics solution for ScottishPower."
-ends-
For further information please contact:
|
Trakm8 Holdings plc |
+44 (0) 174 785 8444 |
|
John Watkins, Executive Chairman |
|
|
James Hedges, Finance Director |
|
|
|
|
|
finnCap (Nomad and broker) |
+44 (0) 20 7220 0500 |
|
Ed Frisby / Simon Hicks – corporate finance |
|
|
Joanna Scott – corporate broking |
|
|
|
|
|
MHP Communications |
+44 (0) 20 3128 8100 |
|
Reg Hoare |
|
|
Jade Neal |
|
About Trakm8
Trakm8 is a UK based Big Data company utilising telematics as its primary enabler. Through IP owned technology, over two billion miles worth of data is collected annually through its fleet management solutions to create and fine tune algorithms used to score driver behaviour, monitor vehicle health and continuously improve the security and operational efficiencies of customers' vehicles.
With its headquarters in Dorset and a manufacturing facility in the West Midlands, the Group supplies a number of well-known customers in the fleet management and insurance sectors across the UK and further afield including customers such as the AA, Saint Gobain, EON, Direct Line Group and Young Marmalade.
The Group's portfolio offers complete telematics solutions, which since the acquisition of the business and assets of DCS Systems, includes dashboard cameras that enable customers to record driving incidents and mitigate the risk from "crash to cash" accidents. This is complemented through a comprehensive hardware range, which includes a self-install unit that is one of the smallest available on the global market.
Recently, the Group acquired Route Monkey, significantly enhancing the Group's logistics solution which offers both route scheduling and optimisation, including routing for electric vehicles.
Trakm8 has been listed on the AIM market of the London Stock Exchange since 2005.
www.trakm8.com / @Trakm8
About Scottish Power
ScottishPower is part of the Iberdrola Group, a global energy company and world leader in wind energy with operations focused in the UK, US, Brazil, Mexico and Spain. ScottishPower operates in the United Kingdom through the following business companies: Scottish Power Generation Holdings Ltd (SPGHL), Scottish Power Energy Networks Holdings Ltd (SPENHL) and ScottishPower Renewable Energy Ltd (SPREL).
Our Generation business produces circa 26k GWh of electricity p.a. our Transmission and Distribution business owns and operates our transmission and distribution network with around 3.3 million customers whilst our Retail business supplies gas and electricity to around 5.7 million customers.
Business Services Fleet is responsible for the procurement, maintenance, repair and disposal of all vehicle requirements for ScottishPower. It is the fleet area's responsibility to ensure the ScottishPower fleet remains compliant in relation to vehicle legal requirement and Operator License responsibility.
This information is provided by RNS
The company news service from the London Stock Exchange
END
CNTUKVSRNOASUAR
CloseNeville Registrars welcomes Belgravium Technologies Plc
Neville Registrars is delighted to welcome Belgravium Technologies Plc as the newest addtion to its list of client companies. Belgravium Technologies Plc is a market leader in enterprise mobile computing solutions with a Global base of over 500,000 installations. Further information can be found on the Company's website: http://www.belgravium-technologies.com/…
Neville Registrars is delighted to welcome Belgravium Technologies Plc as the newest addtion to its list of client companies.
Belgravium Technologies Plc is a market leader in enterprise mobile computing solutions with a Global base of over 500,000 installations.
Further information can be found on the Company's website: http://www.belgravium-technologies.com/
CloseProton Power Systems : New Order
RNS Number : 7281W Proton Power Systems PLC 29 April 2016 29 April 2016 Proton Power Systems plc ("Proton" or the "Company") Order for fuel cell emergency power supply systems in outdoor cabinets Proton Power Systems plc (AIM: PPS), a Clean Tech……
RNS Number : 7281W
Proton Power Systems PLC
29 April 2016
|
|
29 April 2016 |
Proton Power Systems plc
("Proton" or the "Company")
Order for fuel cell emergency power supply systems
in outdoor cabinets
Proton Power Systems plc (AIM: PPS), a Clean Tech total power solution provider, uniquely the designer, developer and producer of fuel cells and fuel cell electric hybrid systems, is pleased to announce, that it has received from a blue chip German customer a significant order for Fuel Cell Emergency Power Units. The total order value is €1.8 million for a number of systems which are all expected to be delivered and installed during 2016. Further orders from this customer for similar applications are expected in 2017 and the following years.
The power range of the units to be delivered to this customer varies from 6 to 8kVA and the units will be contained in outdoor cabinets including hydrogen storage, fuel cells, UPS (Uninterruptible Power Supply) and auxiliary components. These units provide a complete solution based on hydrogen fuel cell technology for long backup time, supplying clean energy for critical loads.
Faiz Francoise Nahab Ph.D., CEO of Proton, said: "This is a key milestone that will provide year on year revenue streams as commercialization of our core technology is now realized. Our continued investment in our manufacturing capability is now bearing fruits. This is a very important showcase of the company's products as multiple installations with integrated solutions are deployed with this blue chip customer. This order demonstrates our expertise in providing complete solutions with a fuel cell as part of a UPS system with a very long backup time. The combination of fuel cell and UPS technology allows us to design complete solutions also for customers with high power rating requirements. We are confident that our business will see an increase in demand for hydrogen based applications in 2016 and beyond ".
– Ends –
For further information:
|
Proton Power Systems plc |
|
|
Dr Faiz Nahab, CEO |
|
|
Achim Loecher, FD Ian Peden, Chairman |
Tel: +49 (0) 89 127 626 550 Tel: +49 (0) 162 101 6470
|
|
|
www.protonpowersystems.com |
|
Stockdale Securities Limited Nominated adviser and broker |
Tel: +44 (0) 20 7601 6100 |
|
Antonio Bossi / David Coaten |
www.stockdalesecurities.com |
|
|
|
About Proton Motor
Proton Motor is an expert in industrial fuel cells, fuel cell and hybrid systems with more than 21 years of experience in this sector. Based in Puchheim near Munich, Proton Motor offers complete fuel cell and hybrid systems from a single source – from the development and production through the implementation of customized solutions. The focus of Proton Motor is on mobile, marine and stationary solutions and applications. The product portfolio consists of base-fuel cell systems, standard complete systems, as well as customized systems.
Proton Motor acquired and integrated SPower GmbH in 2013. Established in 2007, SPower serves IT, Telecoms, public infrastructure and healthcare customers in Germany, Europe and Middle East with power supply solutions for DC and AC power demand. In addition to power supply, SPower also offers solutions for Solar Systems as well as a new product line for Solar Energy Storage. With the SPower expertise, Proton Motor can offer complete power supply solutions with fuel cell and all electrical components.
Proton Motor Fuel Cells GmbH is wholly owned subsidiary of Proton Power Systems plc. The Company has been listed on the London Stock Exchange since October 2006 (code: PPS).
This information is provided by RNS
The company news service from the London Stock Exchange
END
CNTEASLPALXKEFF
CloseFirst Derivatives : Strategic Partnership with Thomson Reuters
RNS Number : 4184W First Derivatives PLC 27 April 2016 First Derivatives plc ("FD" or the "Group") Strategic Partnership with Thomson Reuters for Streaming Analytics FD (AIM: FDP.L, ESM: FDP.I) announces a strategic partnership for the use of its Kx technology with Thomson Reuters to power the……
RNS Number : 4184W
First Derivatives PLC
27 April 2016
First Derivatives plc
("FD" or the "Group")
Strategic Partnership with Thomson Reuters for Streaming Analytics
FD (AIM: FDP.L, ESM: FDP.I) announces a strategic partnership for the use of its Kx technology with Thomson Reuters to power the latest version of their financial Data as a Service platform, Velocity Analytics. The agreement follows a comprehensive review of real-time and in-memory technologies by Thomson Reuters.
Velocity Analytics combines real-time and reference data with Thomson Reuters' deep tick history database to provide clients with market data for use by quantitative analysts, traders and compliance departments across the financial services industry. It provides both pre-built and custom analytics on enriched market data from more than 70 exchange, broker and vendor data sources. This enables clients to create their own data repository for analytics, compliance and other use cases.
A growing pipeline of buy-side and sell-side firms are currently evaluating the service, with several strategic customers engaged in an early adoption programme. The service will be delivered from the world's largest private financial markets Cloud network, Thomson Reuters Elektron.
Mike Powell, managing director for enterprise capabilities, Financial & Risk, at Thomson Reuters, commented: "Given Thomson Reuters' global customer footprint and the demand across the industry for streaming analytics and market insight driven by increasingly quantitative trading strategies and regulatory reporting requirements, demand should be strong for this solution. We are pleased to be working with FD to power Velocity Analytics using Kx technology."
Brian Conlon, Chief Executive Officer of FD, commented: "FD is pleased to partner with Thomson Reuters, using the ability of our Kx technology to enable real-time analytics on very large datasets to power the Velocity Analytics service. This agreement significantly increases our channel to market and the service will be rapidly deployed to customers through Thomson Reuters Elektron, which will accelerate our growth in this market."
Enquiries
For further information please contact:
|
First Derivatives plc Brian Conlon, Chief Executive Officer Graham Ferguson, Chief Financial Officer Ian Mitchell, Head of Investor Relations |
+44(0)28 3025 2242 |
|
|
|
|
Investec Bank plc (Nominated Adviser and Broker) Dominic Emery Carlton Nelson Sebastian Lawrence |
+44 (0)20 7597 4000 |
|
|
|
|
Goodbody (ESM Adviser and Broker) Linda Hickey Finbarr Griffin |
+353 1 667 0420 |
|
|
|
|
Walbrook PR Paul Cornelius / Nick Rome / Helen Cresswell / Sam Allen
|
+44 (0)20 7933 8780
|
About FD
FD is a global technology provider with 20 years of experience. The Group's Kx technology is used by some of the world's largest finance, technology and energy institutions. FD employs over 1,500 people worldwide and has operations in London, New York, Stockholm, Singapore, Hong Kong, Tokyo, Sydney, Palo Alto, Toronto, Philadelphia, Dublin, Belfast and its headquarters in Newry.
For further information, please visit www.firstderivatives.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCEASLKALFKEFF
CloseNasstar PLC : Nasstar PLC Announces Microsoft Gold Certification
RNS Number : 3121W Nasstar PLC 26 April 2016 The Quest for Microsoft Gold: Nasstar PLC Announces Their Microsoft Gold Certification LONDON, UNITED KINGDOM–(Marketwired – April 26, 2016) – Nasstar PLC (LSE: NASA) today announced that they had achieved the coveted Microsoft Gold Hosting Partner certification for their datacenter hosting operations. ……
RNS Number : 3121W
Nasstar PLC
26 April 2016
The Quest for Microsoft Gold: Nasstar PLC Announces Their Microsoft Gold Certification
LONDON, UNITED KINGDOM–(Marketwired – April 26, 2016) – Nasstar PLC (LSE: NASA) today announced that they had achieved the coveted Microsoft Gold Hosting Partner certification for their datacenter hosting operations.
Nasstar PLC is now an accredited Microsoft Gold Hosting Partner, certified by Microsoft and able to deliver solutions that meet Microsoft's stringent demands within its field of expertise.
The Microsoft Gold Hosting Partner accreditation certifies that Nasstar PLC has an in-depth and highly qualified technical resource, a proven track record in delivery and strict procedures and guidelines that are adhered to in each and every hosted solution provided.
Nasstar CEO Nigel Redwood said today, "Achieving our Microsoft Gold Hosting Certification was an important milestone for Nasstar and our technical team, senior management and board of directors are all justifiably proud of this fantastic achievement."
Nasstar Head of Infrastructure Shannon Johnston said today, "The certification process is incredibly hard and rightly so, it encompasses customer references, employee certifications, SPLA revenues, technical certification, multiple accreditations and a solid track record."
Nasstar plans to tell the story of their journey through the Microsoft Gold Hosting Partner accreditation process by hosting a webinar entitled The Quest for Microsoft Gold.
The live webinar will be held on Weds May 18 at 11:00 AM BST (London).
To attend the webinar, please register using this link: http://bit.ly/MicrosoftGold
ABOUT NASSTAR PLC: Nasstar PLC is a managed IT services provider to the recruitment, legal, financial, logistics and government sectors. Nasstar provides fully managed and fully hosted IT services from their ISO27001 security standard certified datacenters, encompassing hosted desktops/applications and managed networks.
Nasstar PLC is listed on the London Stock Exchange under the ticker symbol NASA.
Nasstar PLC, Datapoint House, Telford, TF1 7UL, United Kingdom | 01952 225 000
Website: www.nasstar.com INFORMATION
Nasstar PLC
Lydia Cooper
lydia.cooper@e-know.net
www.nasstar.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
ALLUNUVRNVASURR
CloseMidatech Pharma PLC : Midatech announces positive Q-Octreotide data
RNS Number : 2857W Midatech Pharma PLC 26 April 2016 Midatech Pharma PLC ("Midatech" or the "Company") Midatech Pharma announces positive pharmacokinetic data with Q-Octreotide ~ Release profile of Midatech's Q-Octreotide compared favourably with the reference product and current market leader ~ Midatech Pharma (AIM: MTPH; Nasdaq:……
RNS Number : 2857W
Midatech Pharma PLC
26 April 2016
Midatech Pharma PLC
("Midatech" or the "Company")
Midatech Pharma announces positive pharmacokinetic data with Q-Octreotide
~ Release profile of Midatech's Q-Octreotide compared favourably with the reference product and current market leader ~
Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the international specialty pharmaceutical company focused on commercialising and developing products in oncology and other therapeutic areas, today announces positive pharmacokinetic data with its Q-Octreotide programme (MTD201) for the treatment of acromegaly and carcinoid syndrome. The pilot preclinical study confirmed the systemic release profile of Midatech's Q-Octreotide compared favourably with the reference Octreotide product and current market leader, Sandostatin® LAR Depot (Novartis).
Commenting on the announcement, Dr. Jim Phillips, Chief Executive Officer of Midatech Pharma, said: "Q-Octreotide is one of the most advanced of our in-house cancer treatments. Whilst preparing the programme for clinical development, the existing use of Octreotide gives us confidence that this programme can be progressed quickly. We look forward to continuing to develop our internal pipeline of cancer therapies with Q-Octreotide near the front. Furthermore we are delighted now to be progressing with the investment in commercial scale up of production in our Bilbao facility in Spain, which will enable Q-Octreotide and other projects to be manufactured in-house, enabling us to capture more of the integrated value chain."
MTD201, a sustained release version of Octreotide, is used to treat the incapacitating symptoms of metastatic carcinoid tumours, where it suppresses or inhibits the severe diarrhoea and flushing episodes associated with the disease, and to normalise the over-production of growth hormone in people suffering acromegaly who have had inadequate response to other therapies. Midatech plans on submitting its investigational new drug application (IND) to the U.S. Food and Drug Administration (FDA) and begin bio-equivalence studies in late 2016.
Q-Octreotide is a wholly-owned asset of Midatech Pharma and will continue to be developed in-house. Subject to regulatory approval, Midatech expects to commercialize Q-Octreotide in the United States through its Midatech Pharma U.S. subsidiary.
– ENDS –
For more information, please contact:
Midatech Pharma PLC
Jim Phillips, CEO
Tel: +44 (0)1235 841575
www.midatechpharma.com
Panmure Gordon (UK) Limited (Nominated Adviser and Broker)
Corporate Finance
Freddy Crossley / Atholl Tweedie / Duncan Monteith
Corporate Broking
Tom Salvesen
Tel: +44 (0)20 7886 2500
RBC Europe Limited (Joint Broker)
Darrell Uden / Paul Tomasic / Rupert Walford / Thomas Stockman
Tel: +44 (0)207 653 4000
Consilium Strategic Communications (Financial PR)
Mary Jane Elliott / Ivar Milligan / Matthew Neal / Hendrik Thys
Tel: +44 (0)20 3709 5700
Email: midatech@consilium-comms.com
Westwicke Partners (US Investor Relations)
Chris Brinzey
Tel: +1 339 970 2843
Email: chris.brinzey@westwicke.com
Notes for Editors
About Midatech Pharma PLC
Midatech is an international specialty pharmaceutical company focused on oncology and other therapeutic areas with a commercial platform and four marketed products in the US. Midatech's strategy is to develop products in-house in oncology and with partners in other indications, and to accelerate growth organically and through strategic acquisitions. The Company's R&D activities are supported by two breakthrough drug delivery technologies. The Group, listed on AIM: MTPH and Nasdaq: MTP, employs c.100 staff in four countries. For further company information see: www.midatechpharma.com
Forward Looking Statements
Certain statements in this press release may constitute "forward-looking statements" within the meaning of legislation in the United Kingdom and/or United States. Such forward-looking statements include, but are not limited to, statements regarding the anticipated benefits of Q-Octreotide, preclinical results, the filing and timing of an IND with respect to Q-Octreotide and the receipt of any regulatory approvals, commercialization plans and other statements that are not historical fact. Any forward-looking statements are based on currently available data together with management's views and assumptions regarding future events and performance as of the time the statements are made and are subject to risks and uncertainties. We wish to caution you that there are some known and unknown factors that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements, including but not limited to, operational challenges in achieving our strategic objectives and executing plans.
Reference should be made to those documents that Midatech shall file from time to time or announcements that may be made by Midatech in accordance with the London Stock Exchange AIM Rules for Companies ("AIM Rules"), the Disclosure and Transparency Rules ("DTRs") and the rules and regulations promulgated by the US Securities and Exchange Commission ("SEC"), which contains and identifies other important factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements. These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking statements by or concerning Midatech are expressly qualified in their entirety by the cautionary statements above. Except as may be required under the AIM Rules or the DTRs or by relevant law in the United Kingdom or the United States, Midatech does not undertake any obligation to publicly update or revise any forward-looking statements because of new information, future events or otherwise arising.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCLFFLLSFIEFIR
CloseGalileo Resources : Silverton Project Farm-Out
RNS Number : 9542V Galileo Resources PLC 21 April 2016 For immediate release: 14.00 21 April 2016 Galileo Resources Plc ("Galileo" or "the Company") GALILEO EXECUTES EXCLUSIVE AGREEMENT FOR FARM-OUT OF THE COMPANY'S SILVERTON GOLD PROPERTY IN NEVADA USA Galileo is pleased to announce that……
RNS Number : 9542V
Galileo Resources PLC
21 April 2016
For immediate release: 14.00
21 April 2016
Galileo Resources Plc
("Galileo" or "the Company")
GALILEO EXECUTES EXCLUSIVE AGREEMENT FOR FARM-OUT OF THE COMPANY'S SILVERTON GOLD PROPERTY IN NEVADA USA
Galileo is pleased to announce that it has executed a binding and exclusive term sheet ("Exclusive Agreement") with Orogen Gold plc, ("Orogen"), pursuant to which Orogen will have the right to earn-in a 51% interest in the Company's Silverton Gold Silver property ("Silverton" or the "Property") in Nevada, USA, by way of exploration expenditure of US$400,000 (the "First Expenditure") within 18 months on the Property and thereafter the possibility to spend an additional US$1,500,000 (the "Second Expenditure") within 30 months to earn-in a further 24% interest in the Property (the "Farm-out").
The Company will have the right to participate pro rata after the First Expenditure; should it exercise this right it would retain a 49% equity interest in Silverton (as opposed to being diluted down to 25%). The Exclusive Agreement is subject to due diligence, which is anticipated to be completed, within 45 days of signing, including formalisation of the Exclusive Agreement.
Shareholders are advised that Colin Bird is an executive director of both Galileo and Orogen, in which he holds respectively 24.81% and 1.82% of their issued ordinary share capital. In accordance with the requirements of Sections 171 to 177 of the Companies Act 2006, he has abstained from negotiations and the decision making process of the Galileo Board in regard to the Farm-Out and will continue to do so in order to manage any future potential for a conflict of interest in the Property.
Highlights
· Galileo has granted Orogen the right to earn an initial 51% interest in the Silverton project over the 6km² claim area through exploration spend of US$400,000 over 18 months
· Orogen may earn an additional 24% interest in the project through a further exploration spend of US$1.5 million over a subsequent 30 month period
· Previous bedrock and drill sampling outlined an area >0.5g/t Au measuring 1km x 0.5km
· Farm-out allows for outside investment into Silverton and is in line with Galileo's strategy of focusing its available resources on its South African copper projects
· Assay intervals reported by Newcrest (2003) up to 7.62m@ 2.29g/t Au and 10.67m @ 1.0g/t, including 1.52m @ 5.01g/t Au (non-Code compliant)
· Historic silver and gold production from district
· Shear Zone target never drill tested for gold-silver mineralisation; adjacent short holes returned assays up to 1.71g/t Au, 604g/t Ag over 1.52m intervals within wider intervals of lower grades
· This proposed transaction allows Galileo to continue with its key focus on copper
Andrew Sarosi, an executive director of Galileo, has advised the board's non-executive directors and commented: "We are pleased to have entered into this Exclusive Agreement with Orogen, which will allow for an outside party to fund the exploration of Silverton, in particular focusing on a highly anomalous gold shear zone, on which limited vertical drilling (reverse circulation) has been previously carried out, whilst allowing Galileo to retain upside through its residual equity interest.
We intend to focus our resources on copper exploration, for which in March 2016, the Company raised funds primarily for its Concordia copper project in South Africa. This proposed transaction enables Galileo to retain an interest in Silverton, while focussing on its copper mission. Orogen has confirmed to Galileo that it has sufficient funds in place to commence work on the Property."
The Property
The Property is located northeast of Tonopah in the central Pancake Range. The Silverton claim block comprises 72 lode claims staked by Newcrest in March 2002.
Small-scale mining operated in the area from 1930 to 1937 and in 1953. Total production for the district is <100,000 oz. silver, <2,000 oz. gold and <1 ton of antimony. Over the last three decades multiple companies including Olympic Mining, Westgold, Newmont and Pittston have explored the property for gold and silver. Work completed comprised geochemical sampling, fluid inclusion studies, mapping, geophysics and drilling (~45 pre-Newcrest holes).
Since 2002 Newcrest has taken over 1,000 rock chip samples and drilled 42,983 ft in 29 RC (reverse circulation) drill holes.
Geology/Mineralization
The Silverton district occurs at the eastern margin of a caldera complex dated at 34Ma. Both high and low angle faults and fault breccias related to caldera rim tectonics are observed on the property. Rocks consist of Palaeozoic dolomite/limestone detachment blocks surrounded and underlain by Tertiary rhyolite tuffs. Rhyolite dikes have also been mapped along caldera ring fractures and north trending faults.
Tuffs around the Palaeozoic rocks are locally bleached and argillized (kaolinite – clay). Both units are silicified along faults, generally as jasperoid bodies up to 30 ft. wide. Jasperoid also forms flat-lying replacement horizons within volcanic beds. Additional silicification includes, stockwork silica veining and chalcedony +- stibnite-pyrite veins. One to two percent disseminated pyrite and minor stibnite occurs in tuffaceous rocks over a 4mi2 area. Other mineralization includes barite, gypsum, and alunite. Ore-grade gold values are generally associated with veins, strongly veined limestone, and argillized tuff along mineralized structures and adjacent to jasperoid. Most jasperoid bodies themselves contain only low-level gold.
The property contains a >100ppb Au rock chip anomaly measuring 2.5km x 3km. Au, Ag, As, and Hg mineralization are broadly coincident. Within the anomaly, the most significant of three main zones is a NNE trending area (Silverton Shear) >0.5g/t Au measuring 1km x 0.5km and centered on a 100m wide silicified contact between rhyolite to the east and carbonate rocks to the west.
Old vertical drilling on the southern end of the Silverton Shear returned several intervals of 5ft @ 1-5g/t Au and 100-600g/t Ag. The best Newcrest intercept is 25 feet @ 2.3g/t Au in rhyolite tuff.
Geophysics
Resistivity and ground magnetic surveys were completed in 1998 and 1999. Regional aeromagnetics also covered the Property.
Metallurgy
No metallurgical testing has been done on rocks from the Silverton district and potential recoveries are unknown. However, gold occurrence could be fine grained, micron sized, as none is observed in pan concentrates.
Exploration Potential
The geologic environment is similar to disseminated and bonanza epithermal gold mineralisation at the Round Mountain mine Nevada. The Silverton property and area of volcanic rocks to the west are prospective for exposed and concealed oxide and sulphide tuff- and intrusion -hosted disseminated and associated and/or carbonate-hosted bonanza style epithermal gold mineralisation. In the relatively untested area along the 1 km Silverton shear zone, with a 0.1-1.5g/t Au anomaly at surface, the potential exists for bonanza gold silver 'feeder' veins. In addition, low-grade bulk tonnage disseminated gold can also occur in the rhyolite porphyry intrusions, similar to e.g. Kori Kollo in Bolivia.
Additional information on Silverton
Galileo's accounts do not include a specific carrying cost for the Property, which was acquired as part of the acquisition of the unlisted St Vincent Minerals Inc. (SVM) and whose accounts did not include a separate carrying cost for the Property. The only costs associated with the Property and incurred to date by Galileo are the annual Bureau of Land Management and County fees, which amount to approximately US$11,900.
Related Party Transaction
Given Colin Bird's position as CEO of both Galileo and Orogen and his shareholdings of 24.81% and 1.82% respectively, the Farm-Out is a related party transaction under the AIM Rules. Accordingly, Mr Sarosi, Galileo's executive director, and its non-executive directors, having liaised with the Company's Nominated Adviser, consider that the terms of the Farm-Out are fair and reasonable in so far as its shareholders are concerned.
Technical Sign-Off
Andrew Sarosi, Executive Director of Galileo, holds a B.Sc. Metallurgy and M.Sc. Engineering, University of Witwatersrand, is a member of The Institute of Materials, Minerals and Mining and is 'qualified person' as defined under the AIM Rules for Companies and a competent person under the reporting standards. He has approved the release of this announcement.
For further information, please contact:
Further details are available from the Company's website, including its Glenover rare earth and phosphate project, its Nevada gold-copper properties in the USA, as well as a copy of this announcement:
www.galileoresources.com
You can also follow Galileo on Twitter: @GalileoResource
For further information, please contact:
|
Andrew Sarosi, Executive Director |
Tel +44 (0) 1752 221937 /020 7584 2155 |
|
Beaumont Cornish Limited – Nomad Roland Cornish/James Biddle
|
Tel +44 (0) 20 7628 3396 |
|
Beaufort Securities Limited – Broker Jon Belliss |
Tel +44 (0) 20 7382 8416 |
Technical Glossary
Au Gold
Ag Silver
As Arsenic
Breccia a rock composed of broken fragments of minerals or rock cemented together by a fine-grained matrix
Caldera a large volcanic crater, especially one formed by a major eruption leading to the collapse of the mouth of the volcano.
Dike a later vertical rock between two layers of older rock
Epithermal deposition from warm mineralised waters at shallow depth
Hg mercury
Jasperoid rock formed from hydrothermal activity giving rise to Jasper, an opaque, impure variety of silica
Rhyolite an igneous, volcanic rock, of silica-rich composition
Porphyry textural term for an igneous rock consisting of large-grained crystals
Stibnite antimony sulphide mineral the chief ore of antimony
Tectonics geologic process, which controls the structure and properties of the Earth's crust,
Tertiary a geological period of beginning about 65 million years ago
Tuff an igneous rock formed from the products of an explosive volcanic eruption
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCSEDFEFFMSEDL
CloseOxford Pharmascience : Positive Regulatory Advice from MHRA
RNS Number : 5992V Oxford Pharmascience Group PLC 19 April 2016 Oxford Pharmascience Group plc ("Oxford Pharmascience" or "the Company") Oxford Pharmascience Announces Positive Regulatory Advice from MHRA on OXPzeroTM NSAIDs programme Oxford Pharmascience, the specialty pharmaceutical company that redevelops medicines to make them better, safer and easier to……
RNS Number : 5992V
Oxford Pharmascience Group PLC
19 April 2016
Oxford Pharmascience Group plc
("Oxford Pharmascience" or "the Company")
Oxford Pharmascience Announces Positive Regulatory Advice from MHRA on OXPzeroTM NSAIDs programme
Oxford Pharmascience, the specialty pharmaceutical company that redevelops medicines to make them better, safer and easier to take, announces that it has received clear and positive feedback from the Medicines & Healthcare products Regulatory Agency (MHRA) on the UK regulatory pathway to obtain marketing authorisation for OXPzeroTM Ibuprofen.
The Company currently has OXPzeroTM variants of two non-steroidal anti-inflammatory drug (NSAID) molecules in clinical development, OXPzeroTM Ibuprofen and OXPzeroTM Naproxen. These leverage the company's proprietary technology platform which aims to mask the bitter taste and irritation of NSAIDs and to provide reduced risk of gastrointestinal (GI) side effects. Ibuprofen and naproxen are the two dominant NSAID molecules in the pain relief and anti-inflammatory sector, with combined worldwide sales in excess of $5bn per annum.(1) The Company is in ongoing partnering discussions relating to its OXPzeroTM assets.
The recently received feedback follows a scientific advice meeting with the MHRA in early March on the development programme for OXPzeroTM Ibuprofen. Specific key elements of the MHRA feedback received are:
· OXPzeroTM Ibuprofen can be classified as a new salt form of Ibuprofen, not a new active substance or combination product, which greatly simplifies the regulatory pathway
· The phase III study protocol for the product registration application with improved GI safety claim has been clarified
Marcelo Bravo, Chief Executive Officer of Oxford Pharmascience, commented:
"We are very pleased with the outcome of this meeting. The MHRA's feedback has provided clear direction for the pivotal studies required to gain approval of marketing authorisation for OXPzeroTM Ibuprofen. This gives us a clear understanding of the timelines and associated investment required. We believe this puts us in a strong position as we continue with our partnering discussion process for both OXPzeroTM Ibuprofen and Naproxen."
Further information
The Company has obtained confirmation from the MHRA that OXPzeroTM Ibuprofen can be classified as a new salt form of ibuprofen and not a new active substance or combination product which greatly simplifies the regulatory pathway. During this meeting only OXPzeroTM Ibuprofen was discussed, however, it is the Company's opinion that the MHRA feedback received is equally applicable to OXPzeroTM Naproxen and to OXPzeroTM NSAIDs in general. Following this scientific advice meeting, the Company can confirm that the MHRA has provided guidance on its requirements for the pivotal development programme of OXPzeroTM Ibuprofen. The most appropriate legal basis of application for the over-the-counter and prescription strength product marketing authorisation applications was also confirmed – bioequivalent products will follow the 10(3) route, while non-bioequivalent products will follow the 8(3) route and require an additional single dose, dental pain study to prove the efficacy of OXPzeroTM Ibuprofen.
OXPzeroTM Ibuprofen and OXPzeroTM Naproxen compounds have been shown to deliver a range of key benefits that can be leveraged across multiple differentiated product applications. Specifically, by comparison with generic NSAIDs, OXPzeroTM Ibuprofen and OXPzeroTM Naproxen:
· are milder in the GI tract, delivering major reduction in severe GI mucosal damage;
· significantly mask the bitter taste/burn associated with NSAIDs; and
· deliver an attractive PK profile with adaptable drug release properties.
NSAIDs are one of the most widely used classes of drugs, with more than 30 million users worldwide consuming NSAIDs each day.(1)
For further information:
Oxford Pharmascience Group Plc
Marcelo Bravo, Chief Executive +44 20 7554 5875
N+1 Singer (Nominated Adviser and Broker)
Aubrey Powell / Jen Boorer +44 20 7496 3000
About Oxford Pharmascience Group Plc
Oxford Pharmascience Group Plc uses a range of proprietary technology platforms to re-develop existing medicines to make them better, safer or easier to take. The Company does not manufacture or sell its own pharmaceutical products direct to consumers but instead seeks to license its technologies and dossiers to a network of partners, mainly leading pharmaceutical companies with Rx (prescription) and OTC (Over the Counter) branded portfolios.
Oxford Pharmascience Group Plc focuses on existing medicines that are proven to be safe and effective but nevertheless still have associated issues and side effects often affecting compliance. By working with such medicines the Company is able to develop new innovative products for a fraction of the cost, in much quicker timescales and without the high risk of failure associated with developing new drugs.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCGUGDSIBBBGLC
CloseEpistem Holdings plc : Epistem Begins Full Commercial Launch of Genedrive
RNS Number : 4486V Epistem Holdings plc 18 April 2016 RNS Press Release For release: 18 April 2016 Epistem Begins Full Commercial Launch for Genedrive® Tuberculosis Tests in India Genedrive® Enables Early Detection of TB and Antibiotic Resistance Without Need for Central Laboratory Facilities Epistem……
RNS Number : 4486V
Epistem Holdings plc
18 April 2016
RNS Press Release
For release: 18 April 2016
Epistem Begins Full Commercial Launch for Genedrive® Tuberculosis Tests in India
Genedrive® Enables Early Detection of TB and Antibiotic Resistance Without Need for Central Laboratory Facilities
Epistem Holdings Plc (LSE: EHP), the molecular diagnostics, personalised medicine and biotechnology company, announces today that alongside its Indian commercialisation partner, Xcelris Labs, the Company has begun the full commercial launch for its Genedrive® tuberculosis (TB) and antibiotic resistance test.
Xcelris Labs, one of India's leading genomics products and services testing companies, initially intends to target Genedrive® at the country's approximately 5,000 private clinical laboratories to provide rapid point-of-care molecular identification and antibiotic resistance/drug susceptibility testing for TB. This accepted PCR based molecular diagnostic technique has generally only been available through selected large hospital central laboratory settings. Genedrive®'s low system cost, ease of use and robustness has the potential to greatly increase the wider adoption and availablility of sophisticated molecular diagnostic analysis and consequently patients' access to testing in India.
David Budd, CEO of Epistem, commented "Full commercial TB launch in India is an important next step in the commercialisation of Genedrive®. For the majority of patients who cannot access large reference hospitals and clinics, TB testing in India currently relies on conventional technologies such as microscopy and cell culture to detect infection and determine the most appropriate treatment. Genedrive® offers the ability to detect infection and antibiotic resistance in hours rather than days with important implications for more immediate and effective treatment, and the prevention of spread of infection. The target pricing of Genedrive® and TB test cartridges makes our product an attractive commercial and clinical alternative to traditional diagnostic techniques."
Milina Bose, Executive Director and Vice President of Xcelris said "There are more than 30 million smear microscopy tests conducted in India a year with many carried out in smaller and medium sized private laboratories. Our commercial teams are very excited to now be commercialising Genedrive® and will initally be marketing the system and assays to laboratories outside of the traditional public facilities where molecular TB testing now occurs. We believe that providing these laboratories with the ability to carry out molecular testing with Genedrive® will be very attractive to them and impact positively on patient treatment options in India."
– Ends –
For further details please contact:
Epistem Holdings Plc
David Budd: CEO +44 (0)161 606 7258
John Rylands: Finance Director
Peel Hunt LLP
James Steel +44 (0)207 418 8900
Oliver Jackson
Consilium Strategic Communications
Chris Gardner +44 (0)203 709 5700
Matthew Neal
Notes to Editors
About TB
Tuberculosis is the largest single infectious cause of death among young people and adults today and accounts for one quarter of all preventable adult deaths in developing countries. There were 9.6m new cases in 2014. TB can be treated with antibiotics with an 80% success rate but conventional diagnosis for TB is time consuming reliant on older tools. New molecular test approaches are the fastest growing segment in TB testing but existing technologies are not designed to reach out of large hospitals to smaller laboratories where most tests are currently run. Genedrive®'s low cost, speed-to-result, small size and robustness has the potential to extend access to sophisticated molecular testing outside a centralised laboratory setting.
About Epistem
Epistem is a personalised medicine and biotechnology company developing innovative molecular diagnostics and biomarkers alongside providing contract research services to drug development companies. Epistem's Genedrive® is a next-generation Point of Care molecular diagnostic system providing a low cost, rapid, versatile, simple to use and robust diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. Genedrive® aims to provide a 'gold standard' identification of Tuberculosis & antibiotic resistance. The World Health Organisation (WHO) has publicly recommended that nations incorporate new rapid and molecular tests for Tuberculosis into their disease testing programs. The Genedrive® platform and its first Tuberculosis test is now being prepared for launch in India and the Indian sub-continent. Further details can be found at: www.epistem.co.uk and www.genedrive.com
About Xcelris
Xcelris Genomics is part of the global Abellon business group with interests in diverse areas including clean energy, agrisciences, and genomics, as well as various initiatives in education and social development. Throughout India, Xcelris is a leading company in Genomics products and services and is providing diagnostic testing services in the specialised field of Medical Genetics and Nutrigenomics.
This information is provided by RNS
The company news service from the London Stock Exchange
END
PRLIRMBTMBABTTF
Close
Neville Registrars Limited, Neville House, Steelpark Road, Halesowen, B62 8HD
Tel: 0121 585 1131
Email: info@nevilleregistrars.co.uk

© Neville Registrars Limited 2026. All Rights Reserved. Registered in England No. 4770411
